ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Basic/Clinical Science Session

Cannabinoids and Kidney Diseases

October 25, 2020 | 10:00 AM - 12:00 PM

Location: On-Demand

Session Description

This session examines the role of the endocannabinoid system in normal kidney physiology and how alterations of this system using exogenous receptor ligands, including tetrahydrocannabinol (THC) and cannabidiol (CBD), is associated with pathological changes in acute and chronic kidney disease. In addition, the latest clinical data regarding the association of cannabis and cannabinoid use with renal and cardiovascular outcomes are reviewed. The potential utility of exogenous cannabinoids and the endocannabinoid system as a target for therapy in kidney diseases are discussed.

Learning Objective(s)

  • Describe the role of endo- and exocannabinoids in normal renal physiology
  • Summarize the experimental data on the potential role of cannabinoids and endocannabinoid system in pathogenesis of AKI and CKD
  • Outline the available clinical data on the association of cannabis and cannabinoid use with kidney disease-related outcomes
  • Discuss the potential utility of cannabinoids as a target for therapy in AKI, CKD, and ESRD

Learning Pathway(s)

  • Chronic Kidney Disease
  • Acute Kidney Injury

Moderators

  • Denyse Thornley-Brown, MD
  • Christina M. Wyatt, MD

Presentations

  • Role of the Endocannabinoid System and Its Ligands in Normal Renal Physiology
    10:00 AM - 10:30 AM
    Frank Park, PhD 
  • A Nephrologist's Guide to Cannabis and Cannabinoids
    10:30 AM - 11:00 AM
    Joshua L. Rein, DO, FASN 
  • Association of Cannabis and Cannabinoid Use with Outcomes in Kidney Diseases and ESRD
    11:00 AM - 11:30 AM
    Csaba P. Kovesdy, MD, FASN 
  • Cannabinoids and the Endocannabinoid System as a Target for Therapy in Diabetes, CKD, and ESRD
    11:30 AM - 12:00 PM
    Hamid Moradi, MD, FASN